Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials

PET/MRI is an evolving hybrid imaging modality which combines the inherent strengths of MRIs soft-tissue and contrast resolution and PETs functional metabolic capabilities. Bone and soft-tissue sarcoma are a relatively rare tumor entity, relying on MRI for local staging and often on PET/CT for lymph...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical and experimental medicine Vol. 7; no. 3; pp. 640 - 648
Main Authors Partovi, Sasan, Kohan, Andres A, Zipp, Lisa, Faulhaber, Peter, Kosmas, Christos, Ros, Pablo R, Robbin, Mark R
Format Journal Article
LanguageEnglish
Published United States e-Century Publishing Corporation 01.01.2014
Subjects
Original
FDG
molecular hybrid imaging
PET/MRI
sarcoma
PET/CT
Online AccessGet full text

Cover

More Information
Summary:PET/MRI is an evolving hybrid imaging modality which combines the inherent strengths of MRIs soft-tissue and contrast resolution and PETs functional metabolic capabilities. Bone and soft-tissue sarcoma are a relatively rare tumor entity, relying on MRI for local staging and often on PET/CT for lymph node involvement and metastatic spread evaluation. The purpose of this article is to demonstrate the successful use of PET/MRI in two sarcoma patients. We also use these patients as a starting point to discuss how PET/MRI might be of value in sarcoma. Among its potential benefits are: superior TNM staging than either modality alone, decreased radiation dose, more sensitive and specific follow-up and better assessment of treatment response. These potentials need to be investigated in future PET/MRI soft-tissue sarcoma trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Equal contributors.
ISSN:1940-5901
1940-5901